Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence
Authors
Keywords
-
Journal
Viruses-Basel
Volume 7, Issue 7, Pages 3703-3718
Publisher
MDPI AG
Online
2015-07-08
DOI
10.3390/v7072790
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dolutegravir inhibits HIV-1 Env evolution in primary human cells
- (2015) Thibault Mesplède et al. AIDS
- Combination of the R263K and M184I/V Resistance Substitutions against Dolutegravir and Lamivudine Decreases HIV Replicative Capacity
- (2015) Diane N. Singhroy et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- HIV integrase inhibitors: a new era in the treatment of HIV
- (2015) Jose Luis Blanco et al. EXPERT OPINION ON PHARMACOTHERAPY
- Dolutegravir maintains a durable effect against HIV replication in tissue culture even after drug washout
- (2015) Nathan Osman et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial
- (2015) Antoine Chéret et al. LANCET INFECTIOUS DISEASES
- Week 144 Resistance Analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Atazanavir+Ritonavir+Emtricitabine/Tenofovir DF in Antiretroviral-Naïve Patients
- (2015) Rima Kulkarni et al. HIV CLINICAL TRIALS
- Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors
- (2014) Maureen Oliveira et al. AIDS
- Integrase strand transfer inhibitors in the management of HIV-positive individuals
- (2014) Thibault Mesplède et al. ANNALS OF MEDICINE
- Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study
- (2014) Bisher Akil et al. ANTIVIRAL THERAPY
- ING116070: A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir in Cerebrospinal Fluid in HIV-1-Infected, Antiretroviral Therapy-Naive Subjects
- (2014) S. L. Letendre et al. CLINICAL INFECTIOUS DISEASES
- Dolutegravir
- (2014) M.A. Wainberg et al. DRUGS OF THE FUTURE
- A Randomized Open-Label Study of Three- versus Five-Drug Combination Antiretroviral Therapy in Newly HIV-1 Infected Individuals
- (2014) Martin Markowitz et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity
- (2014) T. Mesplede et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study
- (2014) A. Castagna et al. JOURNAL OF INFECTIOUS DISEASES
- Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial
- (2014) François Raffi et al. LANCET
- Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
- (2014) Bonaventura Clotet et al. LANCET
- The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness
- (2014) Melissa Wares et al. Retrovirology
- Metabolism, Excretion, and Mass Balance of the HIV-1 Integrase Inhibitor Dolutegravir in Humans
- (2013) Stephen Castellino et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV negative women
- (2013) Jessica L Adams et al. ANTIVIRAL THERAPY
- What if HIV were unable to develop resistance against a new therapeutic agent?
- (2013) Mark A Wainberg et al. BMC Medicine
- Dolutegravir Pharmacokinetics in the Genital Tract and Colorectum of HIV-Negative Men After Single and Multiple Dosing
- (2013) Benjamin N. Greener et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection
- (2013) Andrew Zolopa et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- A Randomized, Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 Infection
- (2013) Jürgen K. Rockstroh et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- A Randomized Phase 3 Study Comparing Once-Daily Elvitegravir With Twice-Daily Raltegravir in Treatment-Experienced Subjects With HIV-1 infection
- (2013) Richard Elion et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected Patients
- (2013) Jürgen K. Rockstroh et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- A Randomized, Double-Blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Single-Tablet Regimen Efavirenz/Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection
- (2013) David A. Wohl et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- A Randomized, Double-blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection
- (2013) Nathan Clumeck et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy
- (2013) Eugènia Negredo et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Increase in 2–Long Terminal Repeat Circles and Decrease in D-dimer After Raltegravir Intensification in Patients With Treated HIV Infection: A Randomized, Placebo-Controlled Trial
- (2013) Hiroyu Hatano et al. JOURNAL OF INFECTIOUS DISEASES
- Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
- (2013) Pedro Cahn et al. LANCET
- Dolutegravir for treatment of HIV: SPRING forwards?
- (2013) Laura J Waters et al. LANCET
- Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study
- (2013) Francois Raffi et al. LANCET
- Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial
- (2013) François Raffi et al. LANCET INFECTIOUS DISEASES
- Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
- (2013) Sharon L. Walmsley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure
- (2013) Thibault Mesplède et al. Retrovirology
- Elvitegravir: a once-daily inhibitor of HIV-1 integrase
- (2012) Todd Wills et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Dolutegravir for the treatment of HIV
- (2012) Christine Katlama et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study
- (2012) Joseph J. Eron et al. JOURNAL OF INFECTIOUS DISEASES
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
- (2012) Paul E Sax et al. LANCET
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial
- (2012) Edwin DeJesus et al. LANCET
- Resistance to HIV integrase inhibitors
- (2012) Thibault Mesplède et al. Current Opinion in HIV and AIDS
- The development of novel HIV integrase inhibitors and the problem of drug resistance
- (2012) Mark A Wainberg et al. Current Opinion in Virology
- HIV Drug Resistance and the Advent of Integrase Inhibitors
- (2012) Peter K. Quashie et al. Current Infectious Disease Reports
- Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults
- (2011) Sherene Min et al. AIDS
- Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection
- (2011) Calvin Cohen et al. AIDS
- Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy
- (2011) Duncan Chege et al. AIDS
- Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study
- (2011) Josep M Llibre et al. ANTIVIRAL THERAPY
- No Effect of Raltegravir Intensification on Viral Replication Markers in the Blood of HIV-1–Infected Patients Receiving Antiretroviral Therapy
- (2011) Rajesh T. Gandhi et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- A Randomized, Controlled Trial of Raltegravir Intensification in Antiretroviral-treated, HIV-infected Patients with a Suboptimal CD4+ T Cell Response
- (2011) Hiroyu Hatano et al. JOURNAL OF INFECTIOUS DISEASES
- HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications
- (2011) Jose-Luis Blanco et al. JOURNAL OF INFECTIOUS DISEASES
- Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir
- (2011) P. K. Quashie et al. JOURNAL OF VIROLOGY
- Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial
- (2011) Joseph J Eron et al. LANCET INFECTIOUS DISEASES
- Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study
- (2011) Jean-Michel Molina et al. LANCET INFECTIOUS DISEASES
- Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial
- (2011) Jan van Lunzen et al. LANCET INFECTIOUS DISEASES
- Development of Antiretroviral Drug Resistance
- (2011) Mark A. Wainberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Deep Molecular Characterization of HIV-1 Dynamics under Suppressive HAART
- (2011) Maria J. Buzón et al. PLoS Pathogens
- Total Raltegravir Concentrations in Cerebrospinal Fluid Exceed the 50-Percent Inhibitory Concentration for Wild-Type HIV-1
- (2010) D. Croteau et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor
- (2010) Masanori Kobayashi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses
- (2010) Jeffrey L Lennox et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial
- (2010) Rajesh T. Gandhi et al. PLOS MEDICINE
- Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy Volunteers
- (2009) S. Min et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Sustained Antiretroviral Effect of Raltegravir After 96 Weeks of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection
- (2009) Martin Markowitz et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Rapid selection and archiving of mutation E157Q in HIV-1 DNA during short-term low-level replication on a raltegravir-containing regimen
- (2009) J. Ghosn et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now